211 related articles for article (PubMed ID: 37422012)
21. Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.
Evans R; Kimura H; Alexander R; Davies CH; Faessel H; Hartman DS; Ishikawa T; Ratti E; Shimizu K; Suzuki M; Tanaka S; Yukitake H; Dauvilliers Y; Mignot E
Proc Natl Acad Sci U S A; 2022 Aug; 119(35):e2207531119. PubMed ID: 35994639
[TBL] [Abstract][Full Text] [Related]
22. Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.
Dauvilliers Y; Mignot E; Del Río Villegas R; Du Y; Hanson E; Inoue Y; Kadali H; Koundourakis E; Meyer S; Rogers R; Scammell TE; Sheikh SI; Swick T; Szakács Z; von Rosenstiel P; Wu J; Zeitz H; Murthy NV; Plazzi G; von Hehn C
N Engl J Med; 2023 Jul; 389(4):309-321. PubMed ID: 37494485
[TBL] [Abstract][Full Text] [Related]
23. Investigation of New Orexin 2 Receptor Modulators Using
Janockova J; Dolezal R; Nepovimova E; Kobrlova T; Benkova M; Kuca K; Konecny J; Mezeiova E; Melikova M; Hepnarova V; Ring A; Soukup O; Korabecny J
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423961
[TBL] [Abstract][Full Text] [Related]
24. How hypocretin agonists may improve the quality of wake in narcolepsy.
Justinussen JL; Egebjerg C; Kornum BR
Trends Mol Med; 2023 Jan; 29(1):61-69. PubMed ID: 36400667
[TBL] [Abstract][Full Text] [Related]
25. Hypocretin ligand deficiency in narcolepsy: recent basic and clinical insights.
Ritchie C; Okuro M; Kanbayashi T; Nishino S
Curr Neurol Neurosci Rep; 2010 May; 10(3):180-9. PubMed ID: 20425033
[TBL] [Abstract][Full Text] [Related]
26. The sleep-wake cycle, the hypocretin/orexin system and narcolepsy: advances from preclinical research to treatment.
Arias-Carrión O; Bradbury M
CNS Neurol Disord Drug Targets; 2009 Aug; 8(4):232-4. PubMed ID: 19689304
[TBL] [Abstract][Full Text] [Related]
27. Orexin neurons suppress narcolepsy via 2 distinct efferent pathways.
Hasegawa E; Yanagisawa M; Sakurai T; Mieda M
J Clin Invest; 2014 Feb; 124(2):604-16. PubMed ID: 24382351
[TBL] [Abstract][Full Text] [Related]
28. The roles of orexins in sleep/wake regulation.
Mieda M
Neurosci Res; 2017 May; 118():56-65. PubMed ID: 28526554
[TBL] [Abstract][Full Text] [Related]
29. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions.
Zeitzer JM; Nishino S; Mignot E
Trends Pharmacol Sci; 2006 Jul; 27(7):368-74. PubMed ID: 16766052
[TBL] [Abstract][Full Text] [Related]
30. Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice.
Mochizuki T; Arrigoni E; Marcus JN; Clark EL; Yamamoto M; Honer M; Borroni E; Lowell BB; Elmquist JK; Scammell TE
Proc Natl Acad Sci U S A; 2011 Mar; 108(11):4471-6. PubMed ID: 21368172
[TBL] [Abstract][Full Text] [Related]
31. Integrative physiology of orexins and orexin receptors.
Mieda M; Sakurai T
CNS Neurol Disord Drug Targets; 2009 Aug; 8(4):281-95. PubMed ID: 19689310
[TBL] [Abstract][Full Text] [Related]
32. The hypocretin/orexin receptor: therapeutic prospective in sleep disorders.
Nishino S
Expert Opin Investig Drugs; 2007 Nov; 16(11):1785-97. PubMed ID: 17970638
[TBL] [Abstract][Full Text] [Related]
33. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status.
Mieda M; Sakurai T
CNS Drugs; 2013 Feb; 27(2):83-90. PubMed ID: 23359095
[TBL] [Abstract][Full Text] [Related]
34. Differential roles of orexin receptors in the regulation of sleep/wakefulness.
Mieda M; Tsujino N; Sakurai T
Front Endocrinol (Lausanne); 2013; 4():57. PubMed ID: 23730297
[TBL] [Abstract][Full Text] [Related]
35. GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy.
Black SW; Morairty SR; Chen TM; Leung AK; Wisor JP; Yamanaka A; Kilduff TS
J Neurosci; 2014 May; 34(19):6485-94. PubMed ID: 24806675
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the efficacy of the hypocretin/orexin receptor agonists TAK-925 and ARN-776 in narcoleptic orexin/tTA; TetO-DTA mice.
Sun Y; Ranjan A; Tisdale R; Ma SC; Park S; Haire M; Heu J; Morairty SR; Wang X; Rosenbaum DM; Williams NS; De Brabander JK; Kilduff TS
J Sleep Res; 2023 Aug; 32(4):e13839. PubMed ID: 36808670
[TBL] [Abstract][Full Text] [Related]
37. Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function.
Tabuchi S; Tsunematsu T; Black SW; Tominaga M; Maruyama M; Takagi K; Minokoshi Y; Sakurai T; Kilduff TS; Yamanaka A
J Neurosci; 2014 May; 34(19):6495-509. PubMed ID: 24806676
[TBL] [Abstract][Full Text] [Related]
38. A variant in orexin receptor-2 is associated with self-reported daytime sleepiness in the Japanese population.
Miyagawa T; Shimada M; Honda Y; Kodama T; Tokunaga K; Honda M
J Hum Genet; 2022 Jun; 67(6):377-380. PubMed ID: 35034961
[TBL] [Abstract][Full Text] [Related]
39. Cell transplantation: a future therapy for narcolepsy?
Arias-Carrión O; Murillo-Rodríguez E
CNS Neurol Disord Drug Targets; 2009 Aug; 8(4):309-14. PubMed ID: 19689312
[TBL] [Abstract][Full Text] [Related]
40. [Roles of orexin and effects of orexin receptor antagonists].
Sakurai T
Nihon Rinsho; 2015 Jun; 73(6):1023-30. PubMed ID: 26065136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
